Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1978 1
1992 1
1998 3
1999 1
2000 2
2001 8
2002 1
2003 1
2004 3
2005 3
2006 1
2007 5
2008 6
2009 3
2010 4
2011 10
2012 5
2013 9
2014 14
2015 17
2016 22
2017 19
2018 16
2019 22
2020 35
2021 41
2022 31
2023 30
2024 25
2025 37
2026 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

352 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. Among authors: de melo ac. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Frailty syndrome and risks for falling in the elderly community.
Taguchi CK, Menezes PL, Melo ACS, Santana LS, Conceição WRS, Souza GF, Araújo BCL, Silva ARD. Taguchi CK, et al. Among authors: melo acs. Codas. 2022 Aug 8;34(6):e20210025. doi: 10.1590/2317-1782/20212021025pt. eCollection 2022. Codas. 2022. PMID: 35946721 Free PMC article.
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. Among authors: de melo ac. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin E, Takahashi S, Ramone D, Maćkowiak-Matejczyk B, Polastro L, Alia EMG, Colombo N, Makarova Y, Goh JC, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio MJ, Perez J, Yoo SY, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury MG, Tewari KS. Oaknin A, et al. Among authors: de melo ac. Eur J Cancer. 2025 Feb 5;216:115146. doi: 10.1016/j.ejca.2024.115146. Epub 2025 Jan 10. Eur J Cancer. 2025. PMID: 39798514 Clinical Trial.
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
Colombo N, Zsiros E, Parma G, Rulli E, Sebastianelli A, Bidzinski M, Gallardo C, Matanes E, Hasegawa K, Kose F, Magallanes-Maciel M, Herbertson RA, Ananda S, Kroep JR, de Melo AC, Debruyne PR, Kim JW, Sehouli J, Pierre ME, Hietanen S, Zamagni C, Lu X, Monk BJ, Coleman RL, Peng X, Yamada K, Bogusz AM, De La Motte Rouge T, Wu X; ENGOT-ov65/KEYNOTE-B96 investigators. Colombo N, et al. Among authors: de melo ac. Lancet. 2026 Apr 18;407(10538):1525-1537. doi: 10.1016/S0140-6736(26)00602-1. Epub 2026 Apr 10. Lancet. 2026. PMID: 41974150 Clinical Trial.
Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome.
Guimarães GR, Maklouf GR, Teixeira CE, de Oliveira Santos L, Tessarollo NG, de Toledo NE, Serain AF, de Lanna CA, Pretti MA, da Cruz JGV, Falchetti M, Dimas MM, Filgueiras IS, Cabral-Marques O, Ramos RN, de Macedo FC, Rodrigues FR, Bastos NC, da Silva JL, Lummertz da Rocha E, Chaves CBP, de Melo AC, Moraes-Vieira PMM, Mori MA, Boroni M. Guimarães GR, et al. Among authors: de melo ac. Nat Commun. 2024 Jul 7;15(1):5694. doi: 10.1038/s41467-024-49916-4. Nat Commun. 2024. PMID: 38972873 Free PMC article.
Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E/GOG-3041/ENGOT-EN10 trial.
Westin SN, Moore K, Chon HS, Pepin JT, Salinas EA, Starks D, Disilvestro PA, Slomovitz B, Vettus E, Gálvez-Montosa F, Agyemang-Prempeh K, Zagouri F, Kim JW, Gao Q, Mejia FC, De Melo AC, Nishikawa T, Kowgier M, Iyer S, Wang Y, Van Nieuwenhuysen E. Westin SN, et al. Among authors: de melo ac. Gynecol Oncol. 2026 Mar;206:54-64. doi: 10.1016/j.ygyno.2026.01.777. Epub 2026 Feb 13. Gynecol Oncol. 2026. PMID: 41690202 Free article. Clinical Trial.
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
Long GV, Garnett-Benson C, Dolfi S, Ascierto PA, Guo J, Tarhini AA, Chandra S, Muñoz-Couselo E, Del Vecchio M, de Melo AC, Callahan M, Gogas H, Dummer R, Schadendorf D, Koelblinger P, Quereux G, Thomas I, Yu JX, Fisher A, Wang B, Djidel P, Chouzy A, Semaan M, Chen B, Cheong AMY, Tawbi HA. Long GV, et al. Among authors: de melo ac. Nat Med. 2025 Dec;31(12):4301-4309. doi: 10.1038/s41591-025-04032-8. Epub 2025 Oct 18. Nat Med. 2025. PMID: 41109920 Free PMC article. Clinical Trial.
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial.
Oza AM, Lisyanskaya A, Fedenko A, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Kristeleit R. Oza AM, et al. Among authors: de melo ac. Lancet Oncol. 2025 Feb;26(2):249-264. doi: 10.1016/S1470-2045(24)00674-0. Lancet Oncol. 2025. PMID: 39914419 Clinical Trial.
352 results